Effect Of Rosallistat On Parathyroid Hormone In Renal Anemia Of Maintenance Hemodialysis Patients

Objective: Observation the effect of Roxadustat on parathyroid hormone during the treatment of renal anemia in maintenance hemodialysis patients.Methods: The clinical data of maintenance hemodialysis patients with renal anemia treated in the Department of Nephrology of the 908 th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army from January to June 2021 were collected.According to inclusion and exclusion criteria,48 patients were finally included in this study,and their general clinical data,clinical symptoms,anemia indicators and blood biochemical indicators were collected: Gender,age,body mass index(BMI),diabetes,hypertension,smoking history,dialysis medical history,history of hyperlipidemia,hemoglobin(HGB),serum ferritin(SF),red blood cell(RBC),transferrin saturation(TSAT),hematocrit(HCT),triglycerides(TG),total cholesterol(TC),high-density lipoprotein cholesterol(hdl-c)(HDL),low-density lipoprotein(LDL),hypersensitive C-reactive protein(CRP),interleukin-6(IL-6),parathyroid hormone(PTH),calcium(Ca),phosphorus(P).Forty-eight patients were divided into three groups according to parathyroid hormone(PTH)levels.Patients with PTH values less than 150pg/m L were divided into low PTH group,patients with PTH values between(150 ～ 300)pg/m L were divided into normal PTH group,and patients with PTH values less than(300 ～ 500)pg/m L were divided into high PTH group.Patients in three groups were treated with rosalat for 1 month and 3 months.The changes of above indexes in the three groups before treatment,1 month and 3 months were compared,and the effects of rosalat on parathyroid hormone in the treatment of renal anemia in maintenance hemodialysis patients were observed.Results: There was no significant difference in gender,age,and other general data of all patients(P > 0.05).1.Compared with before treatment,the clinical symptoms of dizziness,fatigue,lethargy,palpitation and heart failure were relieved in patients treated with rosalat.After treatment,HGB,RBC and HCT increased in different amplitude,and the difference was statistically significant(P < 0.05).SF had no significant change(P >0.05).TSAT increased significantly,but there was no statistical significance(P > 0.05).Meanwhile,TC,LDL,CRP and IL-6 were all decreased,with statistical significance(P < 0.05).2.There were no significant differences in blood calcium,blood phosphorus and product of calcium and phosphorus among 3 groups before treatment(P > 0.05).From the beginning of treatment to 3 months of treatment,blood calcium,blood phosphorus,PTH,calcium phosphorus product decreased with the increase of treatment time,and the difference was statistically significant(P < 0.05).Conclusion: Rosalstatat can effectively relieve the symptoms of renal anemia in patients with maintenance hemodialysis,improve the indicators of anemia,reduce the levels of lipid metabolism and inflammatory factors,and regulate the metabolism of calcium and phosphorus,and reduce the level of parathyroid hormone.